Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and
herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up
to 24 hours after administration of 3% SPL7013 in the vagina. There is no hypothesis for this
study.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Starpharma Pty Ltd
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)